Avalo Therapeutics, Inc. Balance Sheet
AVTX|9 years of annual SEC 10-K data (FY2017-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 9 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$116M
FY2025
Cash
$16M
Cash and equivalents
Total Debt
N/A
FY2025
Shareholder Equity
$83M
FY2025
Avalo Therapeutics, Inc. had $116M in total assets and $83M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.59 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -94.2% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.9M | $134.5M | $7.4M | $13.2M | $54.6M | $18.9M | $3.6M | $10.6M | $2.5M |
| Accounts Receivable | - | - | - | $0 | $1.1M | $2.2M | $1.0M | $822.3K | $2.9M |
| Inventory | - | - | $0 | $20.0K | $38.0K | $3.0K | $21.3K | $317.9K | $382.2K |
| Current Assets | $105.3M | $138.9M | $8.4M | $16.4M | $61.8M | $26.0M | $17.7M | $21.9M | $10.7M |
| PP&E (Net) | - | - | - | - | - | - | - | $586.5K | $44.6K |
| Goodwill | $10.5M | $10.5M | $10.5M | $14.4M | $14.4M | $14.4M | $14.4M | $14.4M | $12.3M |
| Total Assets | $116.5M | $150.7M | $21.0M | $33.4M | $80.2M | $43.8M | $36.1M | $70.3M | $42.8M |
| Current Liabilities | $12.9M | $7.0M | $4.6M | $22.1M | $19.9M | $15.2M | $12.2M | $26.2M | $11.1M |
| Total Debt | - | - | - | - | - | - | - | $14.3M | $0 |
| Shareholders' Equity | $83.0M | $133.0M | $7.3M | -$10.9M | $23.1M | $24.6M | $21.0M | $20.9M | $27.9M |